Despite improvements in earnings and sales, Bayer of Germany'sperformance in the first quarter of 1997 has been received by industry observers as disappointing.
Turnover for the group advanced 8.2% to 13.2 billion Deutschemarks ($7.6 billion), with the main reason for the rise being favorable shifts in exchange rates. Sales growth in local currency terms was 3.5%. Bayer said that intense competitive pressure led to an average 2% reduction in prices compared with the same period last year. Volumes advanced 5.5%.
Group pretax earnings were 1.1 billion marks in the quarter, an increase of 5%. It was noted that at Bayer AG, the "totally unsatisfactory" price trend caused pretax income to decline 4.4% to 650 million marks.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze